AmBisome® has improved fungicidal activity vs. echinocandins and azoles.1,2,4,6
Fungicidal activity is particularly important for immunocompromised patients, as their immune systems may not be able to eliminate fungal pathogens alongside a fungistatic agent.7
Use the tabs below to discover more about the activity of different types of antifungal therapy
AmBisome® has a broad spectrum of activity against most fungal pathogens, including those causing rare and difficult-to-treat infections.2-5
Scroll down to discover more about the life-threatening IFIs caused by both common and rare fungal pathogens
In a non-inferiority study (n=531), AmBisome® (3 mg/kg/day) demonstrated efficacy as a 1st-line therapy for proven invasive candidiasis (IC) or candidaemia in patients with a variety of underlying conditions, including haematological disorders and neutropenia.*
Fungal infection was considered to contribute to the cause of death in 9% and 13% of patients in the AmBisome® (n=25) and micafungin (n=34) groups, respectively (p=0.22).13
In a 2007 study, a retrospective analysis found that after 12 weeks the rate of survival in patients with proven (microbiological-confirmed) or probable (based solely on the presence of a halo sign) invasive aspergillosis (IA) treated with AmBisome® (3 mg/kg/day) (n=107) was 72%.†14
Keep scrolling to discover how AmBisome® can help combat the emerging threat of rare and difficult-to-treat infections
In a prospective, multicentre pilot study for the treatment of proven or probable mucormycosis, a combination of high-dose AmBisome® (10 mg/kg/day) and surgery was associated with an overall response rate of 36% (12/33 patients) at Week 4 and 45% (14/31 patients) at Week 12.‡15
In a retrospective study (n=70), the timely initiation (within 6 days of diagnosis) of amphotericin B, the active ingredient in AmBisome®, significantly reduced mortality in patients with haematologic malignancies with definite or probable mucormycosis vs. delayed treatment.¶16
AmBisome® is a treatment of choice for central nervous system (CNS) histoplasmosis, with demonstrated improved survival (10.6 months) compared with amphotericin B lipid complex (8.3 months) (p=0.040).20
In a comparison between two separate closed clinical trials, AmBisome® (3 mg/kg/day) was found to clear the fungal burden of disseminated histoplasmosis in patients with AIDS faster than itraconazole.18
Stay one step ahead of IFIs in your at-risk patients with AmBisome®'s broad-spectrum fungicidal activity and proven clinical efficacy1,2,4,6,10,14,18-21
AIDS: Acquired immune deficiency syndrome; ART: Antiretroviral therapy; EORTC/MSG: European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; HIV: Human immunodeficiency virus; IA: Invasive aspergillosis; IC: Invasive candidaemia; ITT: Intention-to-treat; WHO: World Health Organisation.
Job code: IHQ-AMB-0773
Date of Preparation: November 2022